UPDATE: Morgan Stanley Reiterates On Eli Lilly & Co. On Lackluster Survival Benefit

By: via Benzinga
In a report published Monday, Morgan Stanley analyst David Risinger reiterated an Underweight rating on Eli Lilly & Co. (NYSE: LLY), but ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.